Sutro Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

• Sutro Biopharma Inc STRO.OQ reported a quarterly adjusted loss of 91 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -95 cents. The mean expectation of nine analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -88 cents to -38 cents per share.

• Revenue rose 33.8% to $17.40 million from a year ago; analysts expected $11.61 million.

• Sutro Biopharma Inc's reported EPS for the quarter was a loss of 91 cents​.

• The company reported a quarterly loss of $75.97 million.

• Sutro Biopharma Inc shares had risen by 34.0% this quarter and lost 52.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 17.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Sutro Biopharma Inc is $3.00

This summary was machine generated from LSEG data May 12 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)